ABOUT US

Hope Medicine (HopeMed) is a science-driven, patient-centric, clinical-stage biotech company with research and development bases in major innovation hubs in China. The company was established on the foundation of deep understanding of disease biology and translational medicine, and decades of scientific research in the laboratory of the founder, Professor Rui-Ping Xiao, at Peking University. With a management team of highly accomplished industry veterans combining entrepreneurship and global pharma experience, HopeMed is committed to the discovery, development, and commercialization of innovative, safe, effective, affordable medicines for large, underserved patient populations. Strategically, we are building a robust pipeline in the field of endocrine, cardiovascular and metabolic diseases, with a special focus on women’s health, through internal R&D capabilities, access to external technology platforms to enable a variety of molecular modalities, as well as in-license of complementary and differentiated assets to address unmet medical needs.

Leveraging our extensive KOL network of highly influential academic and clinical experts, we initiated our clinical program following a worldwide exclusive license agreement with Bayer AG on the development and commercialization of a potential first-in-class human antibody (HMI-115) targeting the prolactin receptor for the treatment of endometriosis, androgenic alopecia, and other diseases with dysregulated prolactin signaling.

Our vision is to lead the field of prolactin research and fully explore, develop and commercialize the potential clinical use of HMI-115. Together with a strong internal portfolio, we will strive to become a fully integrated biopharmaceutical company that develops medicines with breakthrough potential to improve the quality of life for patients around the world.